Busy Philipps Highlights ADHD in Women and Her Qelbree Experience

Actress, author, podcaster, and mother of two, Busy Philipps, has joined forces with Supernus Pharmaceuticals to share her journey with attention-deficit/hyperactivity disorder (ADHD). As one of the most common psychiatric diagnoses in adults, ADHD affects millions, yet many women remain undiagnosed until adulthood. Busy Philipps, who has been open about living with ADHD for years, is now highlighting the challenges women face with the condition and the impact proper treatment can have.

Research indicates a significant rise in ADHD diagnoses among women aged 23-29 and 30-49 between 2020 and 2022. Although symptoms often appear in childhood, many women do not receive a diagnosis until they are adults. This delay is often due to gender biases; boys are twice as likely as girls to be diagnosed with ADHD. Boys' symptoms usually fit the hyperactive stereotype, whereas girls' symptoms tend to be inattentive and overlooked. Consequently, many women grow up undiagnosed and untreated, a situation Busy Philipps found herself in.

Philipps has expressed how women often mask or overcompensate for their ADHD symptoms, leading to increased effort to accomplish tasks. She shared that finding the right medication brought her relief, allowing her to manage her symptoms better and determine her priorities. Since starting treatment with Qelbree (viloxazine extended-release capsules), a non-stimulant ADHD medication, she has experienced significant improvements. She aims to empower other women facing similar challenges by promoting the importance of finding appropriate treatment.

The collaboration between Philipps and Supernus Pharmaceuticals coincides with Mental Health Awareness Month, an ideal time to spotlight mental health issues, including the approximately 10 million adults living with ADHD in the United States. Supernus Pharmaceuticals' President and CEO, Jack A. Khattar, emphasized the company's commitment to encouraging those with ADHD to seek treatment and manage their condition. He expressed enthusiasm about the positive impact Qelbree has had on women with ADHD, including Philipps.

Qelbree is a prescription medication used to treat ADHD in adults and children aged six and older. It is important for patients to consult their doctors about all medications they are taking to determine if Qelbree is appropriate for them. However, it comes with safety warnings, including the potential for increased suicidal thoughts and actions, especially during the initial months of treatment or when the dose is adjusted. Patients and caregivers are advised to monitor moods, behaviors, thoughts, and feelings closely during treatment and report any sudden changes to their healthcare provider.

Qelbree is not suitable for individuals taking monoamine oxidase inhibitors (MAOIs) or certain other medications. It can increase blood pressure and heart rate, and it may cause manic episodes in patients with bipolar disorder. Patients should avoid driving or operating heavy machinery until they understand how Qelbree affects them, as it can cause drowsiness or fatigue. Common side effects in children and adolescents include sleepiness, decreased appetite, fatigue, nausea, vomiting, trouble sleeping, and irritability. In adults, these effects can include insomnia, headache, sleepiness, tiredness, nausea, decreased appetite, dry mouth, and constipation.

Busy Philipps's advocacy for ADHD awareness and treatment aims to reduce the stigma and encourage more women to seek help. By sharing her story, she hopes to make a difference for those struggling with ADHD and highlight the importance of appropriate medication and support in managing the condition.